Effect of PTX3 and voriconazole combination in a rat model of invasive pulmonary aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6400-6402

  Lo Giudice, Pietro ^a   Campo, Silvia ^a   De Santis, Rita ^a   Salvatori, Giovanni ^a  

^a Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PENTRAXIN 3; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS FUMIGATUS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; LUNG ASPERGILLOSIS; LUNG FUNCTION; LUNG HEMODYNAMICS; LUNG WEIGHT; MONOTHERAPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE;

ANIMALS; ANTIFUNGAL AGENTS; BODY BURDEN; C-REACTIVE PROTEIN; COLONY COUNT, MICROBIAL; CORTISONE; DRUG COMBINATIONS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LUNG; MANNANS; ORGAN SIZE; PULMONARY ASPERGILLOSIS; PYRIMIDINES; RATS; RESPIRATORY FUNCTION TESTS; SERUM AMYLOID P-COMPONENT; SURVIVAL; TRIAZOLES;

EID: 84869228834     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01000-12     Document Type: Article

References (13)

1. D'Angelo C, et al. 2009. Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J. Immunol. 183:4609-4618.
2. Garlanda C, et al. 2002. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420:182-186.
3. Gaziano R, et al. 2004. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals. Antimicrob. Agents Chemother. 48:4414-4421.
4. Howard SJ, Arendrup MC. 2011. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med. Mycol. 49:S90-S95.
5. Inforzato A, et al. 2008. Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J. Biol. Chem. 283:10147-10161.
6. Inforzato A, et al. 2006. Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation. Biochemistry 45:11540-11551.
7. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715.
8. Lat A, Thompson GR III. 2011. Update on the optimal use of voriconazole for invasive infections. Infect. Drug Resist. 4:43-53.
9. Lo Giudice P, et al. 2010. Efficacy of PTX3 in a rat model of invasive aspergillosis. Antimicrob. Agents Chemother. 54:4513-4515.
10. Simitsopoulou M, et al. 2007. Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus. Antimicrob. Agents Chemother. 51:1048-1054.
11. Simitsopoulou M, et al. 2008. Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: different role of Toll-like receptors. Antimicrob. Agents Chemother. 52:3301-3306.
12. Vora S, Chauhan S, Brummer E, Stevens DA. 1998. Activity of voriconazole with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob. Agents Chemother. 12:2299-2303.
13. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infection Diseases Society of America. Clin. Infect. Dis. 46:327-360.